GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 3.

Slides:

Advertisements

Similar presentations

A. Update on Type 2 Diabetes

Advertisements

Farxiga™ - Dapagliflozin

Phase 2 of new ARVs BMS (maturation inhibitor)

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes.

De Luca A 1,2, Bracciale L 1, Doino M 1, Fabbiani M 1, Sidella L 1, Marzocchetti A 1, Farina S 1, D’Avino A 1, Cauda R 1, Di Giambenedetto S 1 Safety and.

Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.

Practical Considerations in Clinical Management. Guideline-recommended glycemic targets in diabetes A1C (%) FPG (mg/dL) Postprandial glucose (mg/dL) ADA

Journal Club 2009 年 1 月 29 日（木） 8 ： 20 ～ 8 ： 50 B 棟 8 階カンファレンスルーム薬剤部 TTSP 石井英俊.

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach 1 Part 3 of 4.

Amori, R. E. et al. JAMA 2007;298: Efficacy and Safety of Incretin Therapy in Type 2 Diabetes Systematic Review and Meta-analysis 亀田総合病院 1 年目初期研修医.

Switch to ATV-containing regimen  ARIES Study  INDUMA Study  ASSURE Study.

GLP-1 Effectiveness, Mechanisms of Action and Potential Part 2.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 7.

The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes

SGLT-2 Inhibitor with Incretins.

JANUVIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA Tablets contain sitagliptin.

Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 4 of 5.

Improving Outcomes with SGLT2 Cotransporter Inhibitors in Challenging T2DM Patients Part 1.

Adding Prandial Insulin to Basal Insulin: Key Challenges

Int J Clin Pract, December 2013, 67, 12,

Efficacy and Safety of Canaglifozin, a Sodium- Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes Featured Article:

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 4.

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.

Initial Fixed-Dose Combination Therapy With JANUMET™ † (sitagliptin/metformin FDC) vs Metformin Monotherapy 079 Study – Phase A † Trademark of Merck &

SGLT2 inhibitors Ian Gallen Consultant Community Diabetologist

Mania Radfar Pharm.D. Novel oral antidiabetic agents.

Oral hypoGLYCEMICS.

 Insulin Degludec  Ultra long action  Due to formation of soluble multihexamers at the injection site from which monomers gradually separate and are.

GLP-1 agonists Ian Gallen Consultant Community Diabetologist

GLP-1 Agonist:When to start ?

Taieb V, et al. Value Health Nov;18(7):A598.

2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2

6.Fat- increased lipolysis, inc FFA

Dapagliflozin Improves Hyperglycemia and Beta-Cell Function Without Increasing Hypoglycemic Episodes in Patients With Type 2 Diabetes Mellitus Afshin Salsali.

Speaker: Dr. Suman Karmakar Preceptor: Dr. Neetu Jain

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 4.

Foroutan N1,2, Muratov S1,2, Levine M1,2

Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)

Senior Medical Director, Cardiovascular

MK-0431 P051 PDT APPROVED 4/10/09 11/13/2018 2:49 PM

Updates on Emerging GLP-1 Receptor Agonists

EFFICACY AND MECHANISM

SGLT2 Inhibitors in Phase 3 Trials

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 3.

Evaluation of tolerability, pharmacokinetics, and anti-retroviral activity of MK-8591 in treatment-naïve HIV-1-infected adult subjects MK-8591 (EFdA)

Updates Abound.

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.

Antihyperglycemic therapy in type 2 diabetes: general recommendations

CV Risk Management in T2DM: What Did We Learn from ADA 2016?

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

LEADER One Year On.

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Side-by-side comparison of change in A1C with canagliflozin versus DPP-4 inhibitors in randomized clinical trials and the real-world study. *Data are LS.

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.

Carbohydrate absorption inhibitors α-glucosidose inhibitors

Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 6.

Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?

Incretin Physiology in Type 2 Diabetes Mellitus

Glycemic control and body weight over 52 weeks.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS

The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Presentation transcript:

GLP-1 Agonists and DPP-4 Inhibitors How do they work? Part 3

Plasma Levels of Bioactive Intact GLP-1 (9-36)amide After Sitagliptin Administration in T2DM

Sitagliptin Reduces Glucose AUC After a Glucose Load

Sitagliptin Once Daily Improves Both Fasting and Postmeal Glucose Concentration

Sitagliptin Monotherapy and Coadministration With Metformin

Sitagliptin: Proportion of Patients Achieving A1C Goals

Sitagliptin: Active-Comparator (Glipizide) Add-on to Metformin

Sitagliptin: Effect on Baseline A1C

Clinical Adverse Events in Active- Comparator Add-on to Metformin Study Patients With Adverse Events, n (%) Sitagliptin 100 mg (n=588) Glipizide (n=584) One or more AEs419(71.3)444(76.0) Drug-related AEs85(14.5)177(30.3) Serious AEs (SAEs)43( 7.3)44( 7.5) Serious drug-related AEs0( 0.0)2( 0.3) Died1( 0.2)2( 0.3) Discontinued due to AEs16( 2.7)21( 3.6) Discontinued due to drug-related AEs8( 1.4)8 Discontinued due to SAEs6( 1.0)7( 1.2) Discontinued due to serious drug-related AEs0( 0.0)0 Stein P. ADA 66th Scientific Sessions; June 9-14, 2006; Washington DC. Late-breaking abstracts.

Sitagliptin and Measures of  -Cell Function

Sitagliptin: B-Cell Response to Glucose

Vildagliptin Studies: Summary 1

Sitagliptin Studies: Summary 1